Status:

Red

Decision Date:

August 2022

Comments

RED: NICE TA808 - Fenfluramine is recommended as an add‑on to other anti-seizure medicines for treating seizures associated with Dravet syndrome in people aged 2 years and older,

RED: for treatment of seizures associated with Lennox-Gastaut syndrome as an add-on therapy to other anti-epileptic medicines for patients aged ≥2 years. (Decision date -  Sep 2023)

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
• 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again